Skip to content

Treatment of the Medial Meniscus With the NUsurface(R) Meniscus Implant

Treatment of the Medial Meniscus With the NUsurface(R) Meniscus Implant

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01712191
Enrollment
128
Registered
2012-10-23
Start date
2011-01-01
Completion date
2016-03-01
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus; Degeneration, Osteoarthritis, Knee

Keywords

NUsurface, Meniscus, Knee, KOOS

Brief summary

This is a prospective, multi-center, open label, non-randomized study, evaluating the treating of medial meniscus deficiency with the NUsurface Meniscus Implant.

Interventions

DEVICENUsurface Meniscus Implant

Sponsors

Phoenix Kinetics
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Have a degenerative and/or torn meniscus and/or previous meniscectomy as confirmed by diagnostic MRI. 2. Have a pain score of 75 or less on the KOOS pain scale, with 100 being normal. 3. Be in neutral alignment +/- 5 degrees of the mechanical axis. 4. Be between age 35 and 75 at the time of the planned surgery. 5. Be able to be fitted anatomically with a size 30 to 90 NUsurface® device. 6. Have a normal mental status. 7. Be willing and able to attend all follow up visits, complete all study questionnaires, and undergo required X-ray and MRI schedule. 8. Be able and willing to understand and sign the informed consent form.

Exclusion criteria

1. Have evidence of a Grade IV articular cartilage loss on the medial tibial plateau or femoral condyle that could contact the NUsurface implant 2. Have lateral compartment pain with lateral articular cartilage damage greater than Grade II (OB), and/or a lateral meniscus tear(s) 3. Have a varus or valgus knee deformity \> 5 degrees. 4. Have a laxity level of more than II (ICRS), secondary to previous injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL). 5. Have patella instability or non-anatomically positioned patella 6. Have patellar compartment pain and/or patellar articular cartilage damage greater than Grade II (OB). 7. Need a tibial osteotomy at the time of surgery. 8. Have an ACL reconstruction performed less than 9 months before implanting the NUsurface® device 9. Have any type of previously implanted prosthetic meniscus or ligament or knee implant made of plastic. 10. Have a knee flexion contracture \> 10 degrees 11. Be unable to flex the knee to 90 degrees 12. Have a leg length discrepancy causing a noticeable limp. 13. Have had a previous major knee condyle surgery 14. Present with insufficiency fractures or avascular necrosis of the medial compartment. 15. Have an active infection or tumor. 16. Have any type of knee joint inflammatory disease including Sjogren's syndrome. 17. Have neuropathic knee osteoarthropathy, also known as Charcot joint. 18. Have any medical condition that does not allow arthroscopy at the point of entry to the knee. 19. Be pregnant or is a female intending to become pregnant during the study period. 20. Be mentally incapacitated. 21. Be a prisoner. 22. Be a patient who has economic incentive not to improve (e.g., workman's compensation patient) 23. Be morbidly Obese (BMI \> 35). 24. Is unwilling or unable to have an X-ray, Fluro, or MRI of the affected knee

Design outcomes

Primary

MeasureTime frame
Knee injury and Osteoarthritis Outcome Score (KOOS)24 Months

Countries

Belgium, Germany, Israel, Italy, Netherlands, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026